46_3

Enfermedad meningocócica: desafíos y estrategias en cuidados críticos Andrés Felipe Romero Andrade1 Iván José Ardila Gómez2 Clara Jimena Vargas Vega3

Precop SCP

INTRODUCCIÓN

Volumen 24 Número 2

18

1. Pediatra infectólogo, Hospital Universitario Hernando Moncaleano Perdomo, Clínica Uros; docente, Universidad Surcolombiana.

2. Pediatra intensivista, Clínica Uros, Hospital Universitario de Neiva; docente de posgrado en Pediatría, Universidad Surcolombiana.

3. Residente de Pediatría de III año, Universidad Surcolombiana.

Andrés Felipe Romero Andrade, Iván José Ardila Gómez, Clara Jimena Vargas Vega

MONITORIZACIÓN INVASIVA Y NO INVASIVA % 2%#/-)%.$! ,! -/.)4/2)9!#)>. ./ ).6!3)6! %. 4/$/3 ,/3 0!#)%.4%3 #/. #(/15% 3;04)#/ ).#,58%.$/ ,/3 3)'5)%.4%3 0!2:-%42/3 x 4%-0%2!452! x /7)-%42<! $% 05,3/ x 02%3)>. !24%2)!, x $)52%3)3 x %,%#42/#!2$)/'2!-! #/.4).5/ x %#/'2!&<! %. %, 05.4/ $% !4%.#)>. !2! ,/3 .)=/3 #/. #(/15% 3;04)#/ 4!-");.

3% 35')%2% %, 53/ $% 6!2)!",%3 (%-/$).:-)#!3 !6!.9!$!3 0!2! '5)!2 ,! 2%!.)-!#)>. 8 !*534!2 %, 42!4!-)%.4/ 4!,%3 #/-/

. .)=/3 #/. 3%03)3 8 #/-02/-)3/ 2%30)2!4/2)/ %. #/.4%74/3 $% 2%#523/3 ,)-)4!$/3 3% 2%#/ -)%.$! !$-).)342!2 /7<'%./ #/. 02%3)>. 0/3)4)6! #/.4).5! $% ,! 6<! !;2%! $% "52"5*!3 / 6%.4),!#)>. ./ ).6!3)6! 3) ,! 6%.4),!#)>. -%#:.)#! ./ %3 6)!",% / 3%'52! ! ).45"!#)>. %.$/42!

15%!, 8 %, 3/0/24% 2%30)2!4/2)/ ).6!3)6/ %34:. ).$)#!$/3 #5!.$/ (!8 $%4%2)/2/ 02/'2%3)6/ $% ,! &5.#)>. 2%30)2!4/2)! / #!2$)/6!3#5,!2 / #5!.$/ ./ 3% /"3%26! -%*/2<! ,5%'/ $% ,!3 -%$)$!3 ).)#)!,%3 $% 3/0/24% 3 &5.$!-%.4!, !3%'52!2 5.! !$%#5!$! 2%!.)-!#)>. #/. ,<15)$/3 8 #/-%.9!2 #/. ,! !$-).)342!#)>. $% -%$)#!

-%.4/3 6!3/!#4)6/3 3) 3/. .%#%3!2)/3 !.4%3 $% 02/#%$%2 ! ,! ).45"!#)>. . 0!#)%.4%3 15% 2%15)%2%. 6%.4),!#)>. -%#: .)#! ).6!3)6! 3% 2%#/-)%.$!. ,/3 3)'5)%.4%3 /"*%4)6/3 2%30)2!4/2)/3 x !.4%.%2 5.! 02%3)>. !24%2)!, $% /7<'%./ ! PP +J R VDWXUDFLyQ DUWHULDO $% /7<'%./ !4 QRUPR[HPLD x . #!3/3 $% 3<.$2/-% $% $)&)#5,4!$ 2%30)2!4/ 2)! !'5$! 0%$):42)#/ ,%6% -!.4%.%2 5.! !4 %.42% 8 #/. 02%3)>.

0/3)4)6! !, &).!, $% ,! %30)2!#)>. #- x . 02%3%.#)! $% %.&%2-%$!$ 05,-/.!2 '2!6% 05%$% !#%04!23% 5.! !4 %.42% 8 0!2! %6)4!2 %, 53/ $% 0!2:-%42/3 6%.4),!4/2)/3 ./ 02/4%#4/2%3

x 02%3)>. !24%2)!, ).6!3)6! x %#/#!2$)/'2!-! x 3!452!#)>. 6%./3! #%.42!, $% /7<'%./ #6 x 8 3) %34: $)30/.)",% -/.)4/2)9!#)>. $%, '!34/ #!2$<!#/

/. 2%30%#4/ ! ,/3 0!2:-%42/3 6%.4),!4/2)/3 3% !#/.3%*! -!.4%.%2

$%-:3 3% $%34!#!. /42/3 !30%#4/3 #,!6% $%, -!.%*/ #/-/ %, 2%#/./#)-)%.4/ 02%#/9 ,!

2%!,)9!#)>. $% 025%"!3 $% ,!"/2!4/2)/ ).)#)!,%3 %, 3%'5)-)%.4/ #,<.)#/ 8 %, 53/ $% %3#!,!3 $% '2!6%$!$ %30%#)!,-%.4% %. 0!<3%3 #/. 2%#523/3 ,)-)4!$/3 . %34% #/.4%74/ 3% 2%#/-)%.$! ,!

54),)9!#)>. $% %3#!,!3 #/-/ 0 / #/-/ 02%$)#4/2%3 $% -/24!,)$!$

x 3UHVLyQ PHVHWD FP + x /,?-%.%3 #/22)%.4%3 $% - +' %.

0!#)%.4%3 #/. "!*! $)34%.3)"),)$!$ 05,-/ .!2 / !,4! %,!34!.#)! . !15%,,/3 #/. "!*! %,!34!.#)! 05,-/.!2 05%$%. 54),)9!23% 6/,?

-%.%3 #/22)%.4%3 -:3 !,4/3 0!2! !,#!.9!2 3!452!#)/.%3 $% 3)%-02% 15% ,!

02%3)>. -%3%4! ./ %7#%$! ,/3 #-

Precop SCP

x -/.)4/2)9!#)>. x /"4%.#)>. $% !##%3/ 6%./3/ 0%2)&;2)#/ )$%!,-%.4% %. ,/3 02)-%2/3 #).#/ -).54/3 x /7)'%./4%2!0)! x 2%!.)-!#)>. (<$2)#! x ).)#)/ $% !.4)")>4)#/3 $%.42/ $% ,! 02)-%2! (/2! x !$-).)342!#)>. $% -%$)#!-%.4/3 6!3/!#4)6/3 ! 42!6;3 $% ,! 6%.! 0%2)&;2)#! 3) ./ 3% #5%.4! #/. !##%3/ #%.42!,

OXIGENACIÓN Y MANEJO VENTILATORIO

19 Volumen 24 Número 2

!3 02)-%2!3 ).4%26%.#)/.%3 $%"%. ).#,5)2

Enfermedad meningocócica: desafíos y estrategias en cuidados críticos

-

Precop SCP

FLUIDOTERAPIA

Volumen 24 Número 2

20

Andrés Felipe Romero Andrade, Iván José Ardila Gómez, Clara Jimena Vargas Vega

" !

= %,+0!*/%:*

8

+(+ ) '#

+

= %,+,!."1/%:*

8

8

!/%:* ,1()+* . + %/"1* %:* )%+ 6. %

+(+ ) '# +*/% !. ) '#

) '#

+ +(+/ 8-1% +/ ! ) *0!*%)%!*0+

+*%0+.% ! (+/ ) . +.!/ (8*% +/ ! # /0+ . 8 + !0!*!. ( )%*%/0. %:* ! +(+/ /% $ 4 /%#*+/ ! /+ .! .# $8 .%

!/,17/ ! ) '# + *0!/ /% $ 4 /%#*+/ ! /+ .! .# $8 .%

MANEJO VASOACTIVO )%*%/0. %:* ! )! % )!*0+/ 2 /+ 0%2+/ ! ! +)!*5 . 0 * ,.+*0+ +)+ /! +*/% !.! *! !/ .%+ 10%(%5 * + !/+ ,!.%"7.% + +* /+(1 %+*!/ %(1% / + !/+ %*0. :/!+ /% "1!. *! !/ .%+ ! .! +)%!* %*% % . ( )%*%/0. %:* ! )! % )!*0+/ 2 /+ 0%2+/ !/,17/ ! $ !. )%*%/0. + ) '# ! (8-1% +/ ! .! *%) %:* /% !( , %!*0! ;* ,.!/!*0 /%#*+/ (8*% +/ + , .6)!0.+/ ! )+*%0+.%5 %:* +), 0% (!/ +* $%,+,!."1/%:* %* !) .#+ !/0+/ "6.) +/ ,1! !* %*% % ./! %* (1/+ *0!/

.!* (%* !/+ 2!*+/+ ,!.%"7.% + + %*0. :/!+

+. .!* (%* & !/%/0!* % 2 / 1( . ,! .%"7.%

! ( *5 . !/! 2+(1)!* /% !( *%9+ )1!/0. /%#*+/ ! /+ .! .# ! 2+(1)!* + /% !3%/0!* +0. / (%)%0 %+*!/ , . +*0%*1 . +* ( )% *%/0. %:* ! (8-1% +/ .!* (%* !/ !( "6.) + ! ,.%)!. !(! %:* 4 /! .!/!.2 ( *+. .!* (%* , . -1!((+/ /+/ !* (+/ -1! !3%/0 !2% !* % (8*% + ! )+*%0+ .%5 %:* ! 1* .!/%/0!* % 2 / 1( . ,!.%"7.% %/)%*1% /0 !/0. 0!#% !/06 .!/, ( ,+.

1* !*/ 4+ (8*% + ,.+/,! 0%2+ (! 0+.%5 + 4 + (! %!#+ .! (%5 + !* )7.% 0%* !( 1 ( !)+/0.: -1! !( 1/+ 0!),. *+ ! .!* (%*

Precop SCP

+*/% !.! Ĺ ".! 1!* % $ /0 ) '# /% + ) '# *+

21 Volumen 24 Número 2

%,+2+(!)% !2% !*0! ,7. % / !(!2 / 0!. !.+/ !/, %+/

+

Enfermedad meningocócica: desafíos y estrategias en cuidados críticos

Precop SCP

ANTIBIÓTICOS

Volumen 24 Número 2

22

Andrés Felipe Romero Andrade, Iván José Ardila Gómez, Clara Jimena Vargas Vega

" ! ! * * ! ! * " ! * ( ! ! * * ! & ! ! * " " !

( ! % ! " ( ! * ! " ' ! " ! $ ( ! * " + (

! * " * * ! * ! *

QUIMIOPROFILAXIS POSTERIOR A LA EXPOSICIÓN ! % * ! " " * " " $ $

TERAPIA ADYUVANTE Terapia endocrina ! ' & * ! * ( ! * $ " ! ! % " ! $ * ! ! ! " ! " % ! & " " $ ! ( ! * ! ) ! ' ! * * ! ! ! ! % ! ' * " "

Terapia nutricional & % ! " ! *

Precop SCP

* % * # " $ ! ' ! " * ( ! '

!' ( ! * & $

$ !( !

! # ' ! ! * ! * $ ! # ! ! # ! ! " ! * * ! #

" " * ! # * (

! " ( ( $ ! " ! ' ! #

23 Volumen 24 Número 2

!

Enfermedad meningocócica: desafíos en cuidados críticos Abordaje clínico y terapéutico de ylaestrategias enfermedad meningocócica

,4/ 2*&3(/

6LWXDFLRQHV HVSHFtÀFDV

/.4"$4/ %/-*$*,*"2*/

4XLPLRSURÀOD[LV /.4"$4/ &. (5"2%&2<"3 / 02&&3$/,"2 %52".4& ,/3 %<"3 02&6*/3 ", *.*$*/ 2&$/-&.%"%" %& ,/3 3<.4/-"3 70/3*$*>. %*2&$4" " 3&$2&$*/.&3 %&, $"3/ <.%*$& #&3/3 $/-0"24*2 54&.3*,*/3 $&0*,,/3 %& %*&.4&3 &.42& /42/3 &".*-"$*>. #/$" " #/$" / $/.4"$4/ ./ 02/4&(*%/ %52".4& *.45#"$*>. &.%/42"15&", %&3%& %<"3 ".4&3 )"34" ) %&305;3 %&, *.*$*/ %& 42" WDPLHQWR DQWLPLFURELDQR HÀFD] "#&2 %/2-*%/ '2&$5&.4&-&.4& &. ," -*3-" 6*6*&.%" 15& &, $"3/ <.%* $& %52".4& ,/3 %<"3 02&6*/3 ", *.*$*/ %& ,/3 3<.4/-"3 "3"+&2/3 3&.4"%/3 %*2&$4"-&.4& +5.4/ ", $"3/ <.%*$& &. 65&,/3 %& -:3 %& ) %& 05&24" " 05&24" / " 5." %*34".$*" %& 5. "3*&.4/ 3* &, 0"$*&.

4& 4/3<" / 6/-*4"#"

"+/ 2*&3(/

/.4"$4/ $"35", 3*. &70/3*$*>. %*2&$4" " 3&$2&$*/.&3 /2",&3 %&, $"3/ 4XLPLRSURÀOD[LV <.%*$& 0/2 &+&-0,/ &3$5&," / 42"#"+/ 2&$/-&.%"%" /.4"$4/ *.%*2&$4/ ?.*$"-&.4& $/. ",(5*&. %& ",4/ 2*&3(/ 3*. $/.4"$ 4/ $/. &, $"3/ <.%*$& &23/.", 3".*4"2*/ 3*. &70/3*$*>. %*2&$4" " 3&$2&$*/.&3 /2",&3

Precop SCP

. #2/4& / &23/."3 15& ./ 0&24&.&$&. " (250/3 %& ",4/ 2*&3(/ "(250"$*>. %& $"3/3

Volumen 24 Número 2

24

4XLPLRSURÀOD[LV 3/,/ ,5&(/ %& ," $/.35,4" $/.

"54/2*%"%&3 %& 3",5% 0?#,*$" ,/$",&3

%"04"%" %& &.*.(/$/$$", .'&$4*/.3 . *-#&2,*. ! &4 ", &%*4/2&3 -&2*$". $"%&-8 /' &%*"42*$3 0

.542*$*/.", *.*$*", 8 0&2*>%*$" *%&",-&.4& $/. ," 0"24*$*0"$*>. %& 5. &30&$*",*34" &. .542*$*>. . 2&,"$*>. $/. ," .542*$*>. &.4&2", &34" %&#& *.*$*"23& %&.42/ %& ,"3 02*-&2"3 )/2"3 &. .*=/3 )&-/%*.:-*$"-&.4& &34"#,&3 8 $/.

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

. $5".4/ " ," .542*$*>. 0"2&.4&2", &34" %&#& *.*$*"23& ?.*$"-&.4& $5".%/ ," 6<" &.4&2", &34; $/.42"*.%*$"%" / ./ 3&" 4/,&2"%" / 3& 2&$/ -*&.%" 2&",*9"2 -/%*'*$"$*/.&3 &30&$<'*$"3 &. ," .542*$*>. 0"2&.4&2", $/-/ "+534"2 ," (,5$/3" 8 ,/3 "-*./:$*%/3 / "%-*.*342"2 *.35,*." $/. &, /#+&4*6/ %& &34*-5,"2 ," 3<.4&3*3 %& ",#?-*."

"-0/$/ 3& 2&$/-*&.%" &, 53/ %& &-5,3*/.&3 ,*0<%*$"3 &30&$*",*9"%"3 .* ," 350,&-&.4"$*>. &-0<2*$" $/. (,54"-*." "2(*.*." 3&,&.*/ 9*.$ / 6*4"-*." 3",6/ &. $"3/ %& %&'*$*&.$*" %/$5-&.4"%"

Terapias con hemoderivados /. 2&30&$4/ " ," 42".3'53*>. %& (,>#5,/3 2/+/3 ./ 3& 2&$/-*&.%" 5." &342"4&(*" ,*#&2", %& 42".3'53*>. . .*=/3 )&-/%*.:-*$"-&.4&

Andrés Felipe Romero Andrade, Iván José Ardila Gómez, Clara Jimena Vargas Vega

7DEOD (VTXHPDV GH TXLPLRSURÀOD[LV

(ÀFDFLD

-*%14-'-2%

1)7

1+ /+ 436 (37-7 436 :@% 36%0 '%(% ,

(@%7

327908%6 '32 92 )74)'-%0-78% )2 )0 '%73 () 0%'8%28)7 1)7

-*%14-'-2%

PHV

1+ /+ 436 (37-7 1?<-13 1+ 436 :@% 36%0 '%(% ,

(@%7

3XHGH LQWHUIHULU FRQ OD HÀFDFLD () %28-'32')48-:37 36%0)7 = %0+9237 1)(-'%1)2837 %28-'32:907-:%28)7 = %28-'3%+90%28)7 49)() 1%2',%6 0)28)7 () '328%'83 &0%2(37

)*86-%<32%

%A37

1+ 436 :@% -286%197'90%6

37-7 C2-'%

%6% (-71-29-6 )0 (3036 )2 )0 7-8-3 () -2=)''-B2 (-09-6 '32 0-(3'%@2% %0

)*86-%<32%

%A37

1+ 436 :@% -286%197'90%6

37-7 C2-'%

%6% (-71-29-6 )0 (3036 )2 )0 7-8-3 () -2=)''-B2 (-09-6 '32 0-(3'%@2% %0

&LSURÁR[DFLQD%&

PHV

1+ /+ 1?<-13 1+ 436 :@% 36%0

37-7 C2-'%

E

>-8631-'-2%

E

1+ /+ 1?<-13 1+ 436 :@% 36%0

37-7 C2-'%

3 7) 6)'31-)2(% () *361% 698-2%6-% )59-:%0)28) % 6-*%14-'-2% 4%6% 0% )66%(-'%'-B2 () () 0% 2%73*%6-2+) )2 92 )789(-3 )2 %(90837 .B:)2)7

3 6)'31)2(%(% 4%6% 79 973 )2 4)6732%7 )1&%6%>%(%7 & 6L VH KDQ LGHQWLÀFDGR FHSDV UHVLVWHQWHV D ÁXRURTXLQRORQDV GH )2 92% '3192-(%( '327908%6 0% !%&0% (%48%(% () )2-2+3'3''%0 2*)'8-327 2 -1&)60-2 " )8 %0 )(-83 6)7 1)6-'%2 '%()1= 3* )(-%86-'7 4 %

7DEOD (QIRTXH UHFRPHQGDGR SDUD OD TXLPLRSURÀOD[LV FXDQGR VH KDQ GHWHFWDGR DLVODPLHQWRV LQYDVLYRV UHVLVWHQWHV D FLSURÁR[DFLQD 327908%6 '32 037 *92'-32%6-37 () 7%09( 4C&0-'% 03'%0)7 3 )78%8%0)7 7- 7) ,%2 ()8)'8%(3 %-70%1-)2837 6)7-78)28)7 % FLSURÁR[DFLQD \ GLVFXWLU HO HQIRTXH TXH SXHGH VHU UHÀQDGR GHSHQGLHQGR GH OD HSLGHPLRORJtD ORFDO 6XVSHQGHU HO XVR GH FLSURÁR[DFLQD SDUD OD SURÀOD[LV GH FRQWDFWRV FHUFDQRV FXDQGR VH KD\DQ FXPSOLGR %1&37 '6-8)6-37 91&6%0 )2 )0 ?6)% () '%48%'-B2 (96%28) 92 4)6@3(3 () 1)7)7 '327)'98-:37 ) ,%2 6)4368%(3 (37 3 1?7 '%737 () )2*)61)(%( 1)2-2+3'B'-'% -2:%7-:% '%97%(37 436 ')4%7 6)7-78)2 WHV D FLSURÁR[DFLQD /RV FDVRV FDXVDGRV SRU FHSDV UHVLVWHQWHV D FLSURÁR[DFLQD FRQVWLWX\HQ DO PHQRV HO GH WRGRV ORV '%737 6)4368%(37 () )2*)61)(%( 1)2-2+3'B'-'% -2:%7-:% 5HFHWDU ULIDPSLFLQD FHIWULD[RQD R D]LWURPLFLQD HQ OXJDU GH FLSURÁR[DFLQD FRPR SURÀOD[LV FXDQGR VH KD\DQ %0'%2>%(3 037 '6-8)6-37 91&6%0 ,PSOHPHQWDU OD JXtD DFWXDOL]DGD GH SURÀOD[LV HQ WRGRV ORV FRQGDGRV GHQWUR GHO iUHD GH FDSWDFLyQ R HQ RWUD iUHD JHRJUiÀFD GHWHUPLQDGD SRU ORV IXQFLRQDULRV GH VDOXG S~EOLFD ORFDOHV R HVWDWDOHV 0DQWHQHU OD JXtD DFWXDOL]DGD GH SURÀOD[LV KDVWD TXH KD\DQ SDVDGR PHVHV VLQ TXH VH KD\D UHSRUWDGR QLQJ~Q FDVR GH HQIHUPHGDG PHQLQJRFyFLFD LQYDVLYD FDXVDGR SRU FHSDV UHVLVWHQWHV D FLSURÁR[DFLQD HQ HO ?6)% () '%48%'-B2 (%48%(% () )%08, %6) 63:-()67 0-2-'%0 9-(%2') *36 )2-2+3'3''%0 -7)%7) # 28)62)8$ )28)67 *36 -7)%7) 328630 %2( 6):)28-32 -7432-&0) )2 ,8847 ;;; '(' +3: 1)2-2+3'3''%0 ,'4 '0-2-'%0 +9-(%2') -2()< ,810

Precop SCP

25 Volumen 24 Número 2

Enfermedad meningocócica: desafíos y estrategias en cuidados críticos Abordaje clínico y terapéutico de la enfermedad meningocócica

1?@-.585F-0;? ?1 01.1 /;:?501>-> 8- @>-:?2A ?5J: ?;8-91:@1 ?5 8- 419;38;.5:- 1? 91:;> 01 3 0 1B-8A-:0; ?519<>1 8- <>1?1:/5- 01 05?2A:/5J: ;>3G:5/- %1 ?A351>1 <>121>5> A:50- 01? 01 38J.A8;? >;6;? /;: 91:;? 01 0I-?

01 -89-/1:-951:@; : <-/51:@1? /;: /4;=A1 ?H<@5/; ?5: 1?@-.5850-0 419;05:G95/- :; 1D5?@1 ?A25/51:@1 1B501:/5- <->- 1?@-.81/1> A9.>-81? /8->;? 01 @>-:?2A?5J: #->- 8- @>-:?2A?5J: 01 <8-=A1@-? E <8-?9- :; ?1 >1/;951:0- 8- @>-:?2A?5J: <>;258G/@5/- 01 <8-=A1@-? ?-8B; =A1 18 >1/A1:@; ?1- 5:21>5;> - /H8A8-? 99O E 1D5?@- >51?3; 01 ?-: 3>-0; 018 ?5?@19- :1>B5;?; /1:@>-8 &-9<;/; ?1 >1/;951:0- 18 A?; <>;258G/@5/; 01 <8-?9- 2>1?/; /;:318-0; :5 ?A -095:5?@>-/5J: /;9; 1D<-:?;> 01 B;8A91: ?-8B; 1: <>1?1:/5- 01 /;-3A8;<-@I- 0;/A91:@-0- /;: ?-:3>-0; ; >51?3; 5:95:1:@1 01 ?-:3>-0;

Precop SCP

Manejo del sistema nervioso central en meningitis bacteriana

Volumen 24 Número 2

26

!; ?1 >1/;951:0- >1?@>5:35> 8I=A50;? <;> 01.- 6; 01 8;? >1=A1>5951:@;? 01 9-:@1:5951:@;

%519<>1 =A1 ?1- <;?5.81 ?1 ?A351>1 -095:5?@>-> 8I=A50;? <;> BI- ;>-8 ; 1:@1>-8 !; ?1 >1/;951:0- 18 A?; >A@5:->5; 01 -31:@1? ;?9J@5/;? /;9; 18 385/1>;8 18 9-:5@;8 ; 8- ?;8A/5J: ?-85:- 45<1>@J :5/- !; ;.?@-:@1 ?5 ?1 <>1?1:@- A:- <>1?5J: 5:@>-/>-:1-8 181B-0- /;: >51?3; 01 41>:5-/5J: /1>1.>-8 <A101 /;:?501>->?1 18 A?; @19<;>-8 01 -31:@1? ;?9J@5/;? 1D/1<@A-:0; 18 385/1>;8 - 1:21>910-0 91:5:3;/J/5/- /;:@5:K- ?51: 0; A: 01?-2I; />I@5/; <->- 8;? ?5?@19-? 01 ?-8A0 01.50; - ?A 1B;8A/5J: >G<50- E 181B-0- 9;>@-850-0 - 01@1//5J: <>1/;F 18 5:5/5; 5:9105-@; 018 @>-@-951:@; -:@595/>;.5-:; E 8- 59<8191:@-/5J: ;<;>@A:- 01 91050-? 01 ?;<;>@1 ?;: 2A:0-91:@-81? <->- 916;>-> 18 <>;:J?@5/; ? 1?1:/5-8 2;>@-81/1> 8- >10 01 -@1:/5J: <>59->5- 9105-:@1 /-<-/5@-/5J: /;: @5:A- E <>;@;/;8;? 01 >1?<A1?@- >G<50- <->- 3->-:@5F-> A:- 501:@525/-/5J: @19<>-:- 01 8;? /-?;? E A:- 01>5B-/5J: ;<;>@A:- 1?<1/5-8 91:@1 1: /;:@1D@;? 01 >1/A>?;? 8595@-0;? ': -.;>0-61 5:@13>-8 =A1 /;9.5:1 8- -@1:/5J: <>59->5- 2;>@-81/50- /;: 18 -//1?; - @1>-<5-?

1?<1/5-85F-0-? 1? /8-B1 <->- >10A/5> 8- /->3- 01 1?@- 1:21>910-0 <>1B1:5.81

LECTURAS RECOMENDADAS

;>;:188 $;0>53A1F ) -/1>1? 5:@>- " AF

-:0 #>1B1:@5;: 5?<;:5.81 1: 4@@<? CCC /0/

9-: ;8?@ <50195;8;3E ;2 :B-?5B1 1:5:3;/;//-8

3;B 91:5:3;/;//-8 4/< /85:5/-8 3A50-:/1 5:01D 4@98

5?1-?1 5: ;8;9.5- $1@>;?<1/@5B1 %A>B1588-:/1 -@-.-?1 :-8E?5? :21/@ 5? &41>

0;5 ?

E

1:5:3;/;//-8 :21/@5;:? : 59.1>85: ) -:1>611 $ ->:1@@ E:25180 $ %-CE1> 105@;>1? $10 ;;7

M $1<;>@ ;2 @41 ;995@@11 ;: :21/

1>:G:01F %->951:@; 1 %;AF- ->@5:1F !51@;

@5;A? 5?1-?1? 91>5/-: /-019E ;2 #105-@>5/?

( J<1F 1>/1 1@ -8 -@5: 91>5/-: ;:?1:?A? ;:

< 0;5

% , ,

@41 -:-3191:@ ;2 %1<?5? 5: 4580>1: %;/510-0 -@5 :;-91>5/-:- 01 A50-0;? :@1:?5B;? #105G@>5/;? * -@5:

!-@5;:-8 :?@5@A@1 2;> 1-8@4 -:0 ->1 D/1881:/1

91>5/-: #105-@>5/ :@1:?5B1 ->1 %;/51@E+ % #

1:5:35@5? .-/@1>5-8 -:0 91:5:3;/;//-8 05?1-?1

&-?7 ;>/1 D1/A@5B1 %A99->E :@1:?5B1 ->1 10

$1/;3:5@5;: 05-3:;?5? -:0 9-:-3191:@ ! 3A50185:1

! ! 5?<;:5.81 1: 4@@<? CCC :5/1

0;5

;>3 A7 3A50-:/1 :3

>1?;A>/1? 91:5:35@5? .-/@1>5-8

1-8@4 ->1 #>;B501>? 85:5/-8 A50-:/1 2;> 1:5:3;

-:0 91:5:3;/;//-8 05?1-?1 >1/;3:5@5;: 05-3:;?5? -:0

/;//-8 5?1-?1 * :@1>:1@+ 1:@1>? 2;> 5?1-?1 ;:@>;8

9-:-3191:@ <02